Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer After Failure or Intolerability to Second-line Standard Treatment

NCT03693547 is registered in ClinicalTrials.gov with Beijing Biostar Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03693547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03693547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer After Failure or Intolerability to Second-line Standard Treatment
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 22, 2019
Completion date
August 10, 2021
Enrollment
26 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer